Zhou-Rui Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhou-Rui Ma has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Qian-Wei Xiong
Department of Surgery, Children's Hospital of Soochow University, Suzhou, 215021, PR China
2 shared publications- Shi-Zhong Cai
Department of Child and Adolescent Healthcare, Children’s Hospital of Soochow University, Suzhou, China
2 shared publications Deyu Weng
Department of Surgery, Nanjing Pukou Central Hospital (Pukou Branch Hospital of Jiangsu Province Hospital), Nanjing, People’s Republic of China
1 shared publicationJianguo Wang
Department of Surgery, Nanjing Pukou Central Hospital (Pukou Branch Hospital of Jiangsu Province Hospital), Nanjing, People’s Republic of China
1 shared publicationLei Shi
Department of Neurosurgery, Affiliated Kunshan Hospital of Jiangsu University, First People's Hospital of Kunshan, Suzhou, 215300, PR China
1 shared publication- Lei Shi
Department of Neurosurgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu, People's Republic of China.
1 shared publication
Latest Publications
- 17 December 2022
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 25 (5) , 1402-1412
PIK3R2 predicts poor outcomes for patients with melanoma and contributes to the malignant progression via PI3K/AKT/NF-κB axis
Background Melanoma is an aggressive form of skin cancer worldwide. Phosphoinositide-3-kinase regulatory subunit 2 (PIK3R2) exerts carcinogenic roles in various tumors. So far, the function and mechanism of PIK3R2 in melanoma are not been fully clarified. Objective We aimed to clarify the role of PIK3R2 in melanoma. Methods PIK3R2 expressions in melanoma clinical tissues and melanoma cells were measured using quantitative real-time PCR and Western blot. In addition, PIK3R2 expressions in different tumor stages of melanoma were determined by immunohistochemistry assay. Meanwhile, PIK3R2 function was evaluated using loss or gain-of-function assays, Cell Counting Kit-8 assay, flow cytometry, and Transwell analysis. Furthermore, PIK3R2 mechanism in melanoma was assessed by a series of rescue experiments. Results PIK3R2 was highly expressed in melanoma tissues and cells, and PIK3R2 expressions were the highest in Stage IV. Functionally, PIK3R2 knockdown repressed melanoma cell proliferation, invasion, epithelial-mesenchymal transition, and facilitated cell apoptosis. Also, PIK3R2 overexpression produced an opposite trend. Mechanistically, PIK3R2 facilitated melanoma progression by activating PI3K/AKT/NF-κB pathway. Furthermore, PIK3R2 knockdown restrained the melanoma tumor growth in vivo. Conclusions PIK3R2 aggravated melanoma by activating PI3K/AKT/NF-κB pathway, prompting that PIK3R2 might be a therapeutic target for melanoma.
- 17 December 2022
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 25 (5) , 1402-1412
PIK3R2 predicts poor outcomes for patients with melanoma and contributes to the malignant progression via PI3K/AKT/NF-κB axis
Background Melanoma is an aggressive form of skin cancer worldwide. Phosphoinositide-3-kinase regulatory subunit 2 (PIK3R2) exerts carcinogenic roles in various tumors. So far, the function and mechanism of PIK3R2 in melanoma are not been fully clarified. Objective We aimed to clarify the role of PIK3R2 in melanoma. Methods PIK3R2 expressions in melanoma clinical tissues and melanoma cells were measured using quantitative real-time PCR and Western blot. In addition, PIK3R2 expressions in different tumor stages of melanoma were determined by immunohistochemistry assay. Meanwhile, PIK3R2 function was evaluated using loss or gain-of-function assays, Cell Counting Kit-8 assay, flow cytometry, and Transwell analysis. Furthermore, PIK3R2 mechanism in melanoma was assessed by a series of rescue experiments. Results PIK3R2 was highly expressed in melanoma tissues and cells, and PIK3R2 expressions were the highest in Stage IV. Functionally, PIK3R2 knockdown repressed melanoma cell proliferation, invasion, epithelial-mesenchymal transition, and facilitated cell apoptosis. Also, PIK3R2 overexpression produced an opposite trend. Mechanistically, PIK3R2 facilitated melanoma progression by activating PI3K/AKT/NF-κB pathway. Furthermore, PIK3R2 knockdown restrained the melanoma tumor growth in vivo. Conclusions PIK3R2 aggravated melanoma by activating PI3K/AKT/NF-κB pathway, prompting that PIK3R2 might be a therapeutic target for melanoma.
- 26 October 2022
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 244, 114874
Discovery of novel analogs of KHS101 as transforming acidic coiled coil containing protein 3 (TACC3) inhibitors for the treatment of glioblastoma
- 26 October 2022
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 244, 114874
Discovery of novel analogs of KHS101 as transforming acidic coiled coil containing protein 3 (TACC3) inhibitors for the treatment of glioblastoma
- 1 October 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 221, 113528
A novel selective mitochondrial-targeted curcumin analog with remarkable cytotoxicity in glioma cells
- 1 October 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 221, 113528
A novel selective mitochondrial-targeted curcumin analog with remarkable cytotoxicity in glioma cells
- Open Access
- 25 March 2021
- Published by Frontiers Media SA in Pathology and Oncology Research
- Vol. 27, 594299
β-Elemene Triggers ROS-dependent Apoptosis in Glioblastoma Cells Through Suppressing STAT3 Signaling Pathway
Glioblastoma is one of the most aggressive primary brain tumors with few treatment strategies. β-Elemene is a sesquiterpene known to have broad spectrum antitumor activity against various cancers. However, the signaling pathways involved in β-elemene induced apoptosis of glioblastoma cells remains poorly understood. In this study, we reported that β-elemene exhibited antiproliferative activity on U87 and SHG-44 cells, and induced cell death through induction of apoptosis. Incubation of these cells with β-elemene led to the activation of caspase-3 and generation of reactive oxygen species (ROS). Western blot assay showed that β-elemene suppressed phosphorylation of STAT3, and subsequently down-regulated the activation of p-JAK2 and p-Src. Moreover, pre-incubation of cells with ROS inhibitor N-acetyl-L-cysteine (NAC) significantly reversed β-elemene-mediated apoptosis effect and down-regulation of JAK2/Src-STAT3 signaling pathway. Overall, our findings implied that generation of ROS and suppression of STAT3 signaling pathway is critical for the apoptotic activity of β-elemene in glioblastoma cells.
- 25 March 2021
- Published by Frontiers Media SA in Pathology and Oncology Research
- Vol. 27, 594299
Open Accessβ-Elemene Triggers ROS-dependent Apoptosis in Glioblastoma Cells Through Suppressing STAT3 Signaling Pathway
Glioblastoma is one of the most aggressive primary brain tumors with few treatment strategies. β-Elemene is a sesquiterpene known to have broad spectrum antitumor activity against various cancers. However, the signaling pathways involved in β-elemene induced apoptosis of glioblastoma cells remains poorly understood. In this study, we reported that β-elemene exhibited antiproliferative activity on U87 and SHG-44 cells, and induced cell death through induction of apoptosis. Incubation of these cells with β-elemene led to the activation of caspase-3 and generation of reactive oxygen species (ROS). Western blot assay showed that β-elemene suppressed phosphorylation of STAT3, and subsequently down-regulated the activation of p-JAK2 and p-Src. Moreover, pre-incubation of cells with ROS inhibitor N-acetyl-L-cysteine (NAC) significantly reversed β-elemene-mediated apoptosis effect and down-regulation of JAK2/Src-STAT3 signaling pathway. Overall, our findings implied that generation of ROS and suppression of STAT3 signaling pathway is critical for the apoptotic activity of β-elemene in glioblastoma cells.